



Toxicological Profile for Disulfoton

August 2022



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breyse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention



Christopher M. Reh, Ph.D.
Associate Director
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

VERSION HISTORY

Date	Description
August 2022	Final toxicological profile released
July 2021	Draft for public comment toxicological profile released
September 2011	Addendum to the toxicological profile released
August 1995	Final toxicological profile released

CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Melanie Buser, M.P.H. (Lead)
Nicolette Roney, M.P.H.
ATSDR, Office of Innovation and Analytics,
Toxicology Section, Atlanta, GA

Adriana Antezana, M.P.H.
Hannah Derrick, B.S.
Andrea Chiger, M.P.H.
Lauren Brown, M.S., DABT
Kaley Beins, M.P.H.
Abt Associates, Rockville, MD

Bob Sonawane, Ph.D.
Bruce Fowler, Ph.D.
Toxicology and Risk Assessment
Consulting Services, Maryland
(subcontractor to Abt Associates)

Kimberly Zaccaria, Ph.D., D.A.B.T.
Jenny Crisman, B.S.
SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:

Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:

ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA.

PEER REVIEWERS

1. Dr. Xiaozhong Yu, MD, MPH, Ph.D., Associate Professor, Environmental Health Science, College of Public Health, University of Georgia, Athens, Georgia
2. Dr. Lucio G. Costa, PharmD, Professor, Environmental Health Director, Toxicology Program, University of Washington, Seattle, Washington
3. Dr. Dale Hattis, Professor, Ph.D., The George Perkins Marsh Institute, Clark University, Worcester, Massachusetts

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers' comments and determine whether changes will be made to the profile based on comments. The peer reviewers' comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.

CONTENTS

DISCLAIMER	ii
FOREWORD	iii
VERSION HISTORY	v
CONTRIBUTORS & REVIEWERS	vi
CONTENTS	viii
LIST OF FIGURES	x
LIST OF TABLES	xi
CHAPTER 1. RELEVANCE TO PUBLIC HEALTH	1
1.1 OVERVIEW AND U.S. EXPOSURES	1
1.2 SUMMARY OF HEALTH EFFECTS	1
1.3 MINIMAL RISK LEVELS (MRLs)	5
CHAPTER 2. HEALTH EFFECTS	9
2.1 INTRODUCTION	9
2.2 DEATH	55
2.3 BODY WEIGHT	57
2.4 RESPIRATORY	59
2.5 CARDIOVASCULAR	61
2.6 GASTROINTESTINAL	61
2.7 HEMATOLOGICAL	63
2.8 MUSCULOSKELETAL	63
2.9 HEPATIC	64
2.10 RENAL	66
2.11 DERMAL	67
2.12 OCULAR	68
2.13 ENDOCRINE	69
2.14 IMMUNOLOGICAL	70
2.15 NEUROLOGICAL	72
2.16 REPRODUCTIVE	82
2.17 DEVELOPMENTAL	83
2.18 OTHER NONCANCER	85
2.19 CANCER	85
2.20 GENOTOXICITY	86
CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS	92
3.1 TOXICOKINETICS	92
3.1.1 Absorption	92
3.1.2 Distribution	94
3.1.3 Metabolism	94
3.1.4 Excretion	98
3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	99
3.1.6 Animal-to-Human Extrapolations	100
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	100
3.3 BIOMARKERS OF EXPOSURE AND EFFECT	102
3.3.1 Biomarkers of Exposure	103

3.3.2	Biomarkers of Effect	105
3.4	INTERACTIONS WITH OTHER CHEMICALS	107
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION		111
4.1	CHEMICAL IDENTITY	111
4.2	PHYSICAL AND CHEMICAL PROPERTIES	111
CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE		113
5.1	OVERVIEW	113
5.2	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	115
5.2.1	Production	115
5.2.2	Import/Export.....	116
5.2.3	Use	116
5.2.4	Disposal.....	116
5.3	RELEASES TO THE ENVIRONMENT.....	117
5.3.1	Air	118
5.3.2	Water.....	118
5.3.3	Soil	118
5.4	ENVIRONMENTAL FATE	119
5.4.1	Transport and Partitioning.....	119
5.4.2	Transformation and Degradation	122
5.5	LEVELS IN THE ENVIRONMENT.....	124
5.5.1	Air	126
5.5.2	Water.....	127
5.5.3	Sediment and Soil	128
5.5.4	Other Media	132
5.6	GENERAL POPULATION EXPOSURE.....	134
5.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	135
CHAPTER 6. ADEQUACY OF THE DATABASE.....		137
6.1	INFORMATION ON HEALTH EFFECTS.....	137
6.2	IDENTIFICATION OF DATA NEEDS	139
6.3	ONGOING STUDIES.....	147
CHAPTER 7. REGULATIONS AND GUIDELINES		148
CHAPTER 8. REFERENCES		150
APPENDICES		
APPENDIX A.	ATSDR MINIMAL RISK LEVEL WORKSHEETS	A-1
APPENDIX B.	LITERATURE SEARCH FRAMEWORK FOR DISULFOTON	B-1
APPENDIX C.	FRAMEWORK FOR ATSDR'S SYSTEMATIC REVIEW OF HEALTH EFFECTS DATA FOR DISULFOTON.....	C-1
APPENDIX D.	USER'S GUIDE.....	D-1
APPENDIX E.	QUICK REFERENCE FOR HEALTH CARE PROVIDERS	E-1
APPENDIX F.	GLOSSARY	F-1
APPENDIX G.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	G-1

LIST OF FIGURES

1-1. Health Effects Found in Animals Following Inhalation Exposure to Disulfoton.....	2
1-2. Health Effects Found in Animals Following Oral Exposure to Disulfoton.....	3
1-3. Summary of Sensitive Targets of Disulfoton – Inhalation	6
1-4. Summary of Sensitive Targets of Disulfoton – Oral	7
2-1. Overview of the Number of Studies Examining Disulfoton Health Effects.....	11
2-2. Levels of Significant Exposure to Disulfoton – Inhalation	17
2-3. Levels of Significant Exposure to Disulfoton – Oral	41
3-1. Metabolic Pathways for Disulfoton	95
5-1. Number of NPL Sites with Disulfoton Contamination.....	113
6-1. Summary of Existing Health Effects Studies on Disulfoton By Route and Endpoint.....	138

LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for Disulfoton.....	8
2-1. Levels of Significant Exposure to Disulfoton – Inhalation	12
2-2. Levels of Significant Exposure to Disulfoton – Oral	22
2-3. Levels of Significant Exposure to Disulfoton – Dermal.....	52
2-4. Genotoxicity of Disulfoton <i>In Vivo</i>	87
2-5. Genotoxicity of Disulfoton <i>In Vitro</i>	88
4-1. Chemical Identity of Disulfoton	111
4-2. Physical and Chemical Properties of Disulfoton.....	112
5-1. Lowest Limit of Detection for Disulfoton Based on Standards.....	125
5-2. Summary of Environmental Levels of Disulfoton.....	125
5-3. Disulfoton Levels in Water, Soil, and Air of National Priorities List (NPL) Sites	126
5-4. Outdoor Air Monitoring Data for Disulfoton	127
5-5. Surface Water Monitoring Data for Disulfoton.....	129
5-6. Concentrations of Disulfoton in Soil and Sediment	131
5-7. Concentrations of Disulfoton in Fish Tissues.....	132
7-1. Regulations and Guidelines Applicable to Disulfoton	148